Welcome to MOLOGEN AG

Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

3 Questions to Dr. Söhngen

DR. MARIOLA SÖHNGEN CEO MOLOGEN AG

Berlin, 20 January 2016 – The biotechnology company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present data on the immunotherapy MGN1703 at the 2016 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, California (21 – 23 January, 2016). The poster will outline the design of the IMPALA trial... [more]

MOLOGEN AG announces that the United States Patent and Trademark Office (PTO) has declared that it will grant a patent (Notice of Allowance) for the combined use of the lead product, immunotherapy MGN1703, with a chemotherapeutic agent. [more]

Interim Report 3rd Quarter 2015

Download PDF (0,4 MB)

Interim Report 2nd Quarter 2015

Download PDF (0,4 MB)

Interim Report 1st Quarter 2015

Download PDF (0,4 MB)

Annual Report 2014

Download PDF (0,4 MB)